Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies : Episode 2
Opinion
Video
Evolution of Testing Strategies for ESR1
The key opinion leaders (KOLs) review the current testing methods for detecting ESR1 mutations and explore the existing strategies employed to overcome or delay the development of these mutations and the associated endocrine resistance in patients with HR+/HER2- metastatic breast cancer.
EP: 1.Prevalence and Testing Strategies for ESR1
Now Viewing
EP: 2.Evolution of Testing Strategies for ESR1
EP: 3.Dynamics of ESR1 Alterations and Serial Liquid Biopsies
EP: 4.Case Presentation 1: PIK3CA Mutation With ESR1 Mutations
EP: 5.EMERALD Study Design and Results for Elacestrant
EP: 6.Evolving Best Practices for ESR1 Testing
EP: 7.Case Presentation 2: Co-mutations in ESR1 and PIK3CA
EP: 8.PIK3CA Mutations and Delivering PI3K Inhibitors
EP: 9.PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors
EP: 10.Combinations and Treatment Sequence Strategies in Breast Cancer
EP: 11.Future Directions and Unmet Needs in HR+ Breast Cancer
EP: 12.Looking Ahead: Expert Future Perspectives in HR+ Breast Cancer
- What are the challenges and limitations of current strategies to overcome or delay the emergence of ESR1 mutations and endocrine resistance?
- Based on the prevalence and impact of ESR1 mutations, what are the key unmet needs in treating this patient population?
Related Videos
Related Content
